<DOC>
	<DOC>NCT02953301</DOC>
	<brief_summary>The purpose of this study is to determine whether resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have recently achieved disease control with previous systemic therapy.</brief_summary>
	<brief_title>Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<criteria>Main Patients with histologically confirmed MF (Stage IIBIVB) or SS in an ongoing complete response (CR), partial response (PR) or stable disease (SD) after at least one prior systemic therapy according to local standards (including but not limited to αinterferon, bexarotene, total skin electron beam irradiation, chemotherapy) [the most recent systemic therapy must have been completed as planned or stopped due to unacceptable toxicity 28 weeks prior to randomisation] Eastern Cooperative Oncology Group (ECOG) status score 02 Adequate haematological, hepatic and renal function Main Patients with progressive disease (PD) Baseline corrected QT (QTc) interval &gt; 500 milliseconds Concurrent use of any other specific antitumour therapy including psoralen photo chemotherapy (PUVA), chemotherapy, immunotherapy, hormonal therapy, radiation therapy, or experimental medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cutaneous T-Cell Lymphoma (CTLC)</keyword>
	<keyword>Maintenance</keyword>
	<keyword>resminostat</keyword>
	<keyword>4SC</keyword>
	<keyword>HDAC</keyword>
	<keyword>Mycosis Fungoides</keyword>
	<keyword>Sézary Syndrome</keyword>
</DOC>